888-969-2592
Kalkine 0
countryflagCA

Aptose Biosciences Inc

Healthcare CA APS

1.22CAD
0.13(11.93%)

Last update at 2025-06-30T18:04:00Z

Day Range

1.101.22
LowHigh

52 Week Range

0.155.80
LowHigh

Fundamentals

  • Previous Close 1.09
  • Market Cap3.01M
  • Volume404
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.93900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-23.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -41.82300M -65.35400M -55.23800M -26.27700M -28.86800M
Minority interest - - - - -
Net income -41.05300M -65.26200M -54.70000M -25.69100M -28.67300M
Selling general administrative 14.43M 19.32M 26.34M 9.90M 10.32M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.53M 0.62M 0.61M 0.61M 0.09M
Ebit -42.59300M -65.44600M -55.77600M -26.86300M -29.06300M
Ebitda -42.06500M -64.82400M -55.16200M -26.25000M -28.97600M
Depreciation and amortization 0.53M 0.62M 0.61M 0.61M 0.09M
Non operating income net other - - - - -
Operating income -42.59300M -65.44600M -55.77600M -26.86300M -29.06300M
Other operating expenses 42.60M 65.45M 55.77M 26.86M 29.11M
Interest expense 0.77M 0.09M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.78M 0.09M 0.52M 0.58M 0.24M
Net interest income 0.79M 0.09M 0.52M 0.57M 0.28M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.77000M -0.09200M -0.53800M -0.58600M -0.19500M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 42.60M 65.45M 55.77M 26.86M 29.11M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.77M 0.09M 0.54M 0.59M 0.20M
Discontinued operations - - - - -
Net income from continuing ops -41.82300M -65.35400M -55.23800M -26.27700M -28.86800M
Net income applicable to common shares -41.82300M -65.35400M -55.23800M -26.27700M -28.86800M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 10.13M 12.99M 51.03M 82.53M 126.26M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.57M 0.60M 0.26M 0.13M 0.13M
Total liab 14.67M 15.89M 13.29M 8.29M 7.35M
Total stockholder equity -4.54300M -2.90100M 37.74M 74.24M 118.92M
Deferred long term liab - - - - -
Other current liab - 11.38M 5.66M 6.02M 4.10M
Common stock - 444.81M 437.52M 437.39M 429.52M
Capital stock 457.40M 444.81M 437.52M 437.39M 429.52M
Retained earnings -540.96700M -515.53700M -464.33000M -422.50700M -357.15300M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 6.15M 9.25M 36.97M 39.11M 117.39M
Cash and equivalents - - 36.37M 38.82M 117.06M
Total current liabilities 4.46M 15.27M 12.28M 8.17M 6.81M
Current deferred revenue - - - - -
Net debt 3.87M -8.23700M -35.66700M -38.54000M -116.31900M
Short term debt - 0.39M 0.30M 0.46M 0.54M
Short long term debt - - - - -
Short long term debt total - 1.01M 1.30M 0.57M 1.07M
Other stockholder equity - 72.15M 68.87M 63.67M 50.86M
Property plant equipment - - 1.51M 0.79M 1.14M
Total current assets 9.53M 11.89M 49.52M 81.74M 125.08M
Long term investments - - - - -
Net tangible assets - - - 74.24M 118.87M
Short term investments - 0.00000M 9.99M 40.01M 5.00M
Net receivables - - - - -
Long term debt 10.02M - - - -
Inventory - - - - -
Accounts payable 1.26M 3.49M 6.33M 1.70M 2.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -4.31600M -4.31800M -4.31600M -4.31600M
Additional paid in capital - - - - -
Common stock total equity - - - - 429.52M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.60M 1.09M 1.51M 0.79M 1.19M
Capital lease obligations 0.62M 1.01M 1.30M 0.57M 1.07M
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 30.07M -34.99600M 12.71M -17.26800M 0.34M
Change to liabilities 0.00000M -0.47200M 0.21M 0.65M 0.73M
Total cashflows from investing activities 30.07M -35.20800M 12.63M -17.37000M 0.01M
Net borrowings - - - - -
Total cash from financing activities 0.12M 0.23M 58.81M 103.45M 27.87M
Change to operating activities - 1.43M -1.01000M 0.77M -0.05300M
Net income -41.82300M -65.35400M -55.23800M -26.27700M -28.86800M
Change in cash -2.14400M -78.27900M 37.55M 64.54M 4.67M
Begin period cash flow 39.11M 117.39M 79.84M 15.30M 10.63M
End period cash flow 36.97M 39.11M 117.39M 79.84M 15.30M
Total cash from operating activities -32.32200M -43.30400M -33.89100M -21.55800M -23.20700M
Issuance of capital stock 0.10M 0.04M 58.40M 93.17M 25.72M
Depreciation 0.53M 0.62M 0.61M 0.61M 0.09M
Other cashflows from investing activities 30.09M -34.99600M 12.71M -17.26800M 0.34M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.12M 0.23M 58.98M 103.89M 27.89M
Other cashflows from financing activities 0.01M 0.19M 0.41M 10.28M 2.15M
Change to netincome - 20.47M 21.53M 2.69M 4.90M
Capital expenditures 0.02M 0.21M 0.08M 0.10M 0.33M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.32M 1.52M -0.26200M 1.89M 0.67M
Stock based compensation 5.21M 12.95M 21.44M 2.30M 4.28M
Other non cash items -0.55100M 6.96M -0.44300M -0.07800M 0.62M
Free cash flow -32.34600M -43.51600M -33.97000M -21.66000M -23.53600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
APS
Aptose Biosciences Inc		 0.13 11.93% 1.22 - - - 68.22 0.07
FRX
Fennec Pharmaceuticals Inc		 -0.04 0.35% 11.29 - 11.95 10.33 57.98 6.90 20.27
EPRX
Eupraxia Pharmaceuticals Inc		 0.42 5.71% 7.77 - - - 82.33 -3.8823
TH
Theratechnologies Inc.		 -0.11 3.35% 3.17 - 24.75 1.75 19.46 1.79 15.71
MSCL
Satellos Bioscience Inc.		 0.03 5.17% 0.61 2.40 - - 1.74 6.47

Reports Covered

Stock Research & News

View All

Profile

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences Inc

66 Wellington Street West, Toronto, ON, Canada, M5K 1E6

Key Executives

Name Title Year Born
Dr. William G. Rice Ph.D. Chairman, Pres, CEO & Chief Accounting Officer 1959
Dr. Rafael Bejar M.D., Ph.D. Sr. VP & Chief Medical Officer 1972
Ms. Janet Clennett C.A. VP of Fin. NA
Mr. Fletcher Payne Sr. VP & CFO 1963
Mr. Roger Davies B.Sc. VP of Operations NA
Mr. Philippe Ledru Sr. VP & Chief Commercial Officer NA
Dr. William G. Rice Ph.D. Chairman, President & CEO 1959
Mr. Fletcher Payne Senior VP, CFO, Chief Business Officer & Secretary 1963
Dr. Rafael Bejar M.D., Ph.D. Senior VP & Chief Medical Officer 1972
Dr. Marc Wiles Ph.D. Senior Vice President of Regulatory Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.